Cantor Fitzgerald initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $7 price target Camp4 is developing ASOs targeting regulatory RNA, with its lead program CMP-SYNGAP-01 aiming to restore SynGAP protein expression in SYNGAP1 haploinsufficiency, with Phase 1 expected in 2H26, the analyst tells investors in a research note. The program resembles an early-stage Dravet-like story, supported by solid preclinical data and a derisked intrathecal ASO approach proven by Spinraza.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMP:
- Camp4 Therapeutics initiated with an Overweight at Cantor Fitzgerald
- CAMP4 Initiates GLP Toxicology Studies for CMP-SYNGAP-01
- Camp4 Therapeutics initiates GLP toxicology studies for CMP-SYNGAP-01
- Promising Prospects for CAMP4 Therapeutics: Buy Rating Affirmed Amid Advancements in CMP-SYNGAP-01 Program and Strong Investor Confidence
- Apple initiated, Hershey upgraded: Wall Street’s top analyst calls